Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions

Modern Pathology

Volumn 21, Issue 9, 2008, Pages 1121-1129

  Rothberg, Bonnie E Gould ^a   Moeder, Christopher B ^a   Kluger, Harriet ^a   Halaban, Ruth ^a   Elder, David E ^b   Murphy, George F ^c   Lazar, Alexander ^d   Prieto, Victor ^d   Duncan, Lynn McDivitt ^e   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cutaneous; Diagnostic; Immunofluorescence; Immunohistochemistry; Melanoma; Nevus

Indexed keywords

BIOLOGICAL MARKER; CYTOPLASM PROTEIN; GLYCOPROTEIN GP 100; MONOCLONAL ANTIBODY HMB 45; NUCLEAR PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MELANOMA; NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; STAINING; TISSUE MICROARRAY;

ANTIGENS, NEOPLASM; CELL NUCLEUS; DIAGNOSIS, DIFFERENTIAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; NEVUS, PIGMENTED; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 50249111470     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.100     Document Type: Article

References (27)

1. Hoashi T, Muller J, Vieira WD, et al. The repeat domain of the melanosomal matrix protein PMEL17/GP100 is required for the formation of organellar fibers. J Biol Chem 2006;281:21198-21208.
2. Valencia JC, Hoashi T, Pawelek JM, et al. Pmel17: controversial indeed but critical to melanocyte function. Pigment Cell Res 2006;19:250-252; author reply 3-7.
3. Satzger I, Volker B, Meier A, et al. Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes. Am J Surg Pathol 2007;31:1175-1180.
4. Yaziji H, Gown AM. Immunohistochemical markers of melanocytic tumors. Int J Surg Pathol 2003;11:11-15.
5. Berson JF, Harper DC, Tenza D, et al. Pmel17 initiates premelanosome morphogenesis within multivesicular bodies. Mol Biol Cell 2001;12:3451-3464.
6. Kushimoto T, Basrur V, Valencia J, et al. A model for melanosome biogenesis based on the purification and analysis of early melanosomes. Proc Natl Acad Sci USA 2001;98:10698-10703.
7. Raposo G, Tenza D, Murphy DM, et al. Distinct protein sorting and localization to premelanosomes, melanosomes, and lysosomes in pigmented melanocytic cells. J Cell Biol 2001;152:809-824.
8. Bergman R, Dromi R, Trau H, et al. The pattern of HMB-45 antibody staining in compound Spitz nevi. Am J Dermatopathol 1995;17:542-546.
9. de Vries TJ, Fourkour A, Wobbes T, et al. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997;57:3223-3229.
10. Lazzaro B, Elder DE, Rebers A, et al. Immunopheno-typing of compound and spitz nevi and vertical growth-phase melanomas using a panel of monoclonal antibodies reactive in paraffin sections. J Invest Dermatol 1993;100:313S-317S.
11. Niezabitowski A, Czajecki K, Rys J, et al. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 1999;70:150-160.
12. Busam KJ, Chen YT, Old LJ, et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 1998;22:976-982.
13. Prieto VG, Woodruff JM. Expression of HMB45 antigen in spindle cell melanoma. J Cutan Pathol 1997;24:580-581.
14. Al-Batran SE, Rafiyan MR, Atmaca A, et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005;65:3937-3941.
15. Hashimoto Y, Ito Y, Kato T, et al. Expression profiles of melanogenesis-related genes and proteins in acquired melanocytic nevus. J Cutan Pathol 2006;33:207-215.
16. Ruiter DJ, Brocker EB. Immunohistochemistry in the evaluation of melanocytic tumors. Semin Diagn Pathol 1993;10:76-91.
17. Smoller BR, McNutt NS, Hsu A. HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma. Am J Surg Pathol 1989;13:680-684.
18. Sun J, Morton Jr TH, Gown AM. Antibody HMB-45 identifies the cells of blue nevi. An immunohistochemical study on paraffin sections. Am J Surg Pathol 1990;14:748-751.
19. Wood WS, Tron VA. Analysis of HMB-45 immunoreactivity in common and cellular blue nevi. J Cutan Pathol 1991;18:261-263.
20. Rimm DL. What brown cannot do for you. Nat Biotechnol 2006;24:914-916.
21. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-1327. Epub 2002 Oct 21.
22. Kallioniemi OP, Wagner U, Kononen J, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10:657-662.
23. Gown AM, Vogel AM, Hoak D, et al. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
24. Crotty KA, Scolyer RA, Li L, et al. Spitz naevus vs Spitzoid melanoma: when and how can they be distinguished? Pathology 2002;34:6-12.
25. Wechsler J, Bastuji-Garin S, Spatz A, et al. Reliability of the histopathologic diagnosis of malignant melanoma in childhood. Arch Dermatol 2002;138:625-628.
26. King MS, Porchia SJ, Hiatt KM. Differentiating Spitzoid melanomas from Spitz nevi through CD99 expression. J Cutan Pathol 2007;34:576-580.
27. McNutt NS, Urmacher C, Hakimian J, et al. Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity. J Cutan Pathol 1995;22:502-517.